We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.
- Authors
Ascha, Mona; Zhou, Xuan; Rao, Youlan; Minai, Omar A.; Tonelli, Adriano R.
- Abstract
Introduction Anticoagulation is a common treatment modality in patients with pulmonary arterial hypertension ( PAH). Further studies are needed to appropriately assess the risk/benefit ratio of anticoagulation, particularly in PAH patients receiving PAH-specific therapies. Aims We use observational long-term data on PAH patients treated with subcutaneous ( SQ) treprostinil from a large open-label study. Patients were followed for up to 4 years. The use of warfarin and bleeding events were recorded. Results At total of 860 patients (age [mean± SD] 46±15 years, 76% female, 83% Caucasian, 49% idiopathic PAH, and 76% New York Heart Association [ NYHA] functional class III) were included. All patients received SQ treprostinil (15% also other pulmonary hypertension [ PH]-therapies) and 590 (69%) received warfarin during the study. The proportions of women, African American, and idiopathic pulmonary hypertension ( IPAH) patients were higher in the group receiving warfarin. A higher proportion of patients with congenital heart disease and portopulmonary hypertension did not receive warfarin. There were no differences in unadjusted long-term survival between PAH patients receiving warfarin or not (log-rank test, P value=.69), even when only considering idiopathic PAH ( P=.32). In addition, no difference was found in adjusted long-term survival both in PAH ( P=.84) and idiopathic PAH patients ( P=.44) based on the use of warfarin. Furthermore, no survival difference based on the use of warfarin were noted between propensity score-matched PAH patients ( P=.37). Conclusions Long-term anticoagulation with warfarin was not associated with any significant effect on survival in PAH or idiopathic PAH patients treated with SQ treprostinil.
- Subjects
WARFARIN; PULMONARY artery diseases; SUBCUTANEOUS infusions; HYPERTENSION; THERAPEUTICS; PULMONARY circulation disorders
- Publication
Cardiovascular Therapeutics, 2017, Vol 35, Issue 5, pn/a
- ISSN
1755-5914
- Publication type
Article
- DOI
10.1111/1755-5922.12281